Cora N. Sternberg

Research interests

Publications

• Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

  New England Journal of Medicine · 2020 · 10.1056/nejmoa2002788

• Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.20.01035

• Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1911206

• Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1800536

• Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1613683

• Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

  European Urology · 2017 · https://doi.org/10.1016/j.eururo.2017.06.002

• Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2015.64.2702

• Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)30107-3

• Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(14)71205-7

• Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

  The Lancet · 2015 · https://doi.org/10.1016/s0140-6736(15)00986-1

• Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1405095

• Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

  New England Journal of Medicine · 2013 · 10.1056/nejmoa1303989

• Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

  The Lancet Oncology · 2012 · 10.1016/s1470-2045(12)70379-0

• Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1207506

• Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)

  The Lancet · 2012 · 10.1016/s0140-6736(12)61253-7

• Abiraterone and Increased Survival in Metastatic Prostate Cancer

  New England Journal of Medicine · 2011 · 10.1056/nejmoa1014618

• Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2011.34.8433

• External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study

  The Lancet Oncology · 2010 · 10.1016/s1470-2045(10)70223-0

• Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2009.23.9764

• Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.12.4487

• Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

  The Lancet · 2002 · 10.1016/s0140-6736(02)09408-4

• Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

  New England Journal of Medicine · 1997 · 10.1056/nejm199707313370502

• Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

  Cancer · 1989 · 10.1002/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7

• Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium

  New England Journal of Medicine · 1988 · 10.1056/nejm198806023182202

• Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the Urothelium

  The Journal of Urology · 1985 · 10.1016/s0022-5347(17)48996-8

Current projects

No projects listed.